High frequency of HBeAg-minus chronic HBsAg-positive liver disease in Egypt

El-Zayadi, Abdel-Rahman; Sober, M.; Lavanchy, Daniel; Hasseeb, N. M.; Selim, Osaima; Mayerat, C.; Dabbous, Helene

doi:10.1016/0928-4346(94)00175-5

Cited by 4 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatitis B e antigen (HBeAg)‐negative disease is predominant in most Middle East countries (Table 2; 59–65), ranging from around 53% to over 90% of HBsAg carriers. The exception appears to be Pakistan; there is very limited data, but HBeAg‐negative disease may account for <20% of HBsAg‐positive adult CHB patients [62,63].…”

Section: Epidemiology Of Hepatitis B In the Middle Eastmentioning

confidence: 99%

A review of chronic hepatitis B epidemiology and management issues in selected countries in the Middle East

2011

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Experts from seven countries convened as a Specialist Panel for the Middle East to share information on practical issues relating to the epidemiology, diagnosis and management of chronic hepatitis B (CHB) infection. The Middle East is regarded as a region of high-to-intermediate epidemicity; however, infant vaccination programmes have successfully lowered the prevalence of hepatitis B infection in most countries to that of low-to-intermediate endemicity. Vaccine issues still to be addressed included improving coverage in some rural/poor communities, instituting hepatitis B vaccine at birth and providing vaccines for high-risk population groups. Hepatitis B infection in the Middle East primarily occurs as a result of perinatal infection, horizontal transmission between family members and transmission from injections. Blood transfusion services have broadly efficient screening programmes, but immunocompromised and haemodialysis patients are at risk. The cost of screening, monitoring and treating CHB influences practice in a number of Middle East countries, and there is a need for information on the most cost-effective options.

show abstract

Section: Epidemiology Of Hepatitis B In the Middle Eastmentioning

confidence: 99%

A review of chronic hepatitis B epidemiology and management issues in selected countries in the Middle East

2011

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…In addition, many of these patients present at an older age with significant hepatic pathology and persistent viral replication [7,8,9]. In addition, our patients have HBV genotype D, the predominant type in Saudi Arabia and other Middle East countries like Egypt [3,23]. Unfortunately, this genotype is known to be associated with the HBeAg-negative variant [6], and with more severe liver disease [7].…”

Section: Discussionmentioning

confidence: 99%

Impact of Liver Biopsy on the Decision to Treat Patients with Chronic Hepatitis B Genotype D Virus Infection

Al‐Qahtani

Al-Ashgar²,

Mana³

et al. 2014

Intervirology

View full text Add to dashboard Cite

Objectives: Patients with chronic hepatitis B virus (HBV) may exhibit significant liver pathology despite alanine aminotransferase (ALT) and HBV DNA levels below the cutoff values advised by treatment guidelines. We evaluated candidacy for HBV therapy when baseline histopathological changes are taken into consideration. Methods: Clinical, biochemical, serological, virological, and histopathological (METAVIR score) data of 117 patients with HBeAg-negative chronic HBV genotype D were collected and analyzed. Results: Significant pathology (≥F2 and/or ≥A2) and fibrosis (≥F2 ± ≥A2) were found in 73 (62.4%) and 59 (50.4%) patients, respectively. Based on HBV DNA (>2,000 IU/ml) and ALT levels >2 × 40 U/l (the standard cutoff value), only 31 (26.5%) patients were candidates for therapy. This increased to 58 (49.6%) patients when the new ALT cutoff values (30 U/l for males, and 19 U/l for females) were applied. Relying on either ≥F2 and/or A ≥2 or ≥F2 ± ≥A2 increases the treatment candidacy to 73 (62.4%) and 59 (50.4%) patients, respectively. Also, when compared with standard ALT cutoff values, applying both new ALT cutoff values with either significant pathology or fibrosis increases treatment candidacy to 28 (23.9%) and 42 (35.9%) patients, respectively. Conclusion: Liver pathology is more reliable than ALT and HBV DNA in the decision to treat patients with HBeAg-negative chronic HBV genotype D.

show abstract

Evaluation of Liver Biopsy in Egyptian HBeAg-Negative Chronic Hepatitis B Patients at Initial Presentation: Implications for Therapy

El-Zayadi

Badran²,

Saied³

et al. 2009

Am J Gastroenterol

View full text Add to dashboard Cite

show abstract

High frequency of HBeAg-minus chronic HBsAg-positive liver disease in Egypt

Cited by 4 publications

References 16 publications

A review of chronic hepatitis B epidemiology and management issues in selected countries in the Middle East

A review of chronic hepatitis B epidemiology and management issues in selected countries in the Middle East

Impact of Liver Biopsy on the Decision to Treat Patients with Chronic Hepatitis B Genotype D Virus Infection

Evaluation of Liver Biopsy in Egyptian HBeAg-Negative Chronic Hepatitis B Patients at Initial Presentation: Implications for Therapy

Contact Info

Product

Resources

About